NEW YORK (GenomeWeb) – Washington University in St. Louis has partnered with ArcherDX to assess minimum residual disease in pediatric acute myeloid leukemia patients.

Researchers plan to use ArcherDX's sequencing technology to analyze 870 patients who are part of a Children's Oncology Group clinical trial that is analyzing different treatment regimens for pediatric AML patients with Down syndrome based on how they respond to an initial induction therapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.